A review of retrospective data on the clinical cases of patients observed at the clinic of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology (RCCMCO&R) of the Ministry of Health of the Republic of Uzbekistan was conducted. During the examination, the clinical case of a patient from practice with atypical localization of the affected areas was isolated and described. The patient was diagnosed with a B-cell variant of lymphoma (B-LBL) with damage to the bone marrow and skeleton bones. High risk. The duration of verification of the diagnosis of BLBL was 5 months, as a result, the patient received inadequate therapy, and the disease progressed, which ultimately negatively affected the outcome of his treatment. Tumor lesion of the skeletal system was a characteristic feature in B-LBL (11.1%), while in the T-cell variant of lymphoma (TLBL), it did not occur. Despite this, this indicator was not reliable in this clinical case.
В структуре внелегочного туберкулеза ведущее место занимает нефротуберкулез. Несмотря на достижения современной медицины, до 80% случаев нефротуберкулез диагностируют в поздних и запущенных стадиях [4]. Информативность того или
иного метода лучевой диагностики нефротуберкулеза зависит от локализации, характера и выраженности деструктивного процесса. Характерные для нефротуберкулеза признаки наблюдаются, как правило, при его далеко зашедших формах и
представлены кавернозными образованиями и различными вариантами кальцификации
The Tashkent Institute of improvement of doctors Results of treatment of 78 bladders sick by a cancer (BCa) with a lesion regional lymph nodes in stages T3-4 N1-2 MO are presented. The recurrent tumor is taped 19 (82,6 %) from 23 patients by whom the radical cystectomy (RCE) with standard lymph node dissection and the subsequent polychemotherapy (PCHT ) (I group was spent). On the average in 5,2 months after the treatment termination; in 11 group of 25 patients after RCE with dilated lymph node
dissection and the subsequent PCHT at 18 (72.0 %) the recurrent tumor, on the average in 4,8 months is taped. In 111 group after carrying out PCHT (without surgical treatment) advance of growth of a tumor after its regress and stabilization, was diagnosed at 27 (90,0 %) from 30
patients, on the average in 3,5 months. The survival rate median in 1 group of patients has made 9,4± 3,6 months, in II group - 12,5±4,2 months and in 111 group - 7,4 ± 2.9 months (p <0,05)